Von Vascular has announced the presentation of new data evaluating its Algo smart pump at the 2025 BRAIN conference (1–3 December, London, UK), with Brian Jankowitz (Hackensack Meridian Neuroscience Institute, Edison, USA) giving an invited lecture highlighting the underlying science of the device’s SMARTstatic aspiration and sharing results from an independently conducted benchtop study showing superiority of Algo over standard static aspiration.
The evaluation—performed using biologic bovine clot analogues in a scientifically justified neurovascular flow model—compared Algo’s SMARTstatic mode to standard static aspiration across 0.06-inch, 0.071-inch and 0.084-inch inner-diameter aspiration catheters.
Under fluoroscopic assessment, Algo consistently demonstrated deeper initial clot corking and longer final clot ingestion across all catheter sizes, Von Vascular claims in a press release. Algo also achieved higher first-pass complete ingestion rates with the 0.06-inch and 0.071-inch catheters while matching performance with the 0.084-inch configuration. Additionally, no embolisation to new territory occurred with Algo in any test condition, whereas the standard static aspiration generated distal emboli—most notably in the 0.071-inch cohort.
Jankowitz noted that these findings build upon prior results published in the Journal of Neurosurgery earlier this year, reinforcing SMARTstatic aspiration as a more intelligent and effective method of mechanical clot removal.
“The Algo smart pump changes the game by giving us precision and power through logic-driven aspiration that we simply haven’t had with legacy pumps,” he added.
Von Vascular says it will integrate these results into its upcoming regulatory milestones, and continues to collaborate with key clinical and strategic partners.
